Open AccessDemethylation and epigenetic modification with 5-azacytidine reduces IDH1 mutant glioma growth in combination with temozolomide
Author(s) -
Alex Shimura Yamashita,
Marina da Costa Rosa,
Alexandra Borodovsky,
William T. Festuccia,
Timothy A. Chan,
Gregory J. Riggins
Publication year - 2018
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/noy146
Subject(s) - idh1 , glioma , temozolomide , chromatin immunoprecipitation , cancer research , isocitrate dehydrogenase , epigenetics , idh2 , biology , mutant , microbiology and biotechnology , chemistry , gene expression , promoter , biochemistry , gene , enzyme
Isocitrate deyhydrogenase (IDH) mutant glioma comprises the majority of grades II-III gliomas and nearly all secondary glioblastomas. These progressive gliomas arise from mutations in IDH1 or IDH2 that pathologically produce D-2-hydroxyglutarate (2HG), which interferes with cell reactions using alpha ketoglutarate, leading to a hypermethylated genome and epigenetic dysregulation of gene expression initiating tumorigenesis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom